This medication has gained approval from the China National Medical Products Administration for use in individuals with locally advanced or metastatic NSCLC who have sensitive EGFR mutations along with the T790M resistance mutation (1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.